Roche leads bispecific monoclonal antibodies market with 40% share in 2024

The Business Research Company says the bispecific monoclonal antibodies market is highly concentrated, with Roche holding 40% of global sales in 2024. The report points to acquisitions, T-cell engagers and precision immunotherapy as the main competitive themes shaping the market through 2035.

Why it matters: - The bispecific monoclonal antibodies market is one of the most concentrated biologics segments, with the top nine players accounting for 53% of revenue in 2024. - High concentration reflects steep barriers to entry in antibody engineering, clinical validation, manufacturing and regulation. - The report points to growing demand across oncology and immune-mediated disorders, where bispecific designs are being used to improve target specificity and therapeutic precision.

What happened: - The Business Research Company published its 2026 bispecific monoclonal antibodies market report, covering market size, trends and a global forecast through 2035. - F. Hoffmann-La Roche AG led global sales in 2024 with a 40% market share. - Amgen held 6% of the market, Johnson & Johnson held 4%, and Immunocore Holdings plc., Akeso Biopharma Co., Ltd., AbbVie Inc. and Pfizer Inc. each held 1%. - Merus held 0.1% of the market, and Jazz Pharmaceuticals plc held 0.004%. - The report lists other major companies in the space, including AstraZeneca, Sanofi, Eli Lilly, Bristol Myers Squibb, Novartis, Bayer, Merck & Co., GSK, Takeda, Innovent Biologics, Kyowa Kirin, Biocon, Zai Lab, Alphamab Oncology, ABL Bio, AbCellera, EpimAb Biotherapeutics, Novo Nordisk and Celldex Therapeutics.

The details: - Roche’s biologics and antibody therapeutics portfolio is positioned around engineered antibody therapies for oncology indications. - The report says leading companies are building differentiated bispecific portfolios, licensing deals and broader targeted therapeutic platforms. - Major raw material suppliers include Thermo Fisher Scientific, Danaher, Sartorius, Merck KGaA’s MilliporeSigma unit, Lonza, FUJIFILM Irvine Scientific, AGC Biologics, Wacker Chemie, Repligen, Avantor, Bio-Rad, Corning, Eppendorf, Miltenyi Biotec, Asahi Kasei, Tosoh, WuXi Biologics, Boehringer Ingelheim BioXcellence, Charles River Laboratories and Sartorius Stedim Biotech. - Major wholesalers and distributors include Cencora, McKesson, Cardinal Health, Owens & Minor, Morris & Dickson, Anda, FFF Enterprises, Medipal Holdings, Zuellig Pharma, Phoenix Group, DKSH, EVERSANA, Movianto, Shanghai Pharma, Sinopharm, BioCareSD, ASD Healthcare, Besse Medical, Henry Schein and PHOENIX Pharmahandel. - Major end users include Mayo Clinic, Cleveland Clinic, MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Mass General Brigham, Kaiser Permanente, Apollo Hospitals, Cleveland Clinic Abu Dhabi, University Hospitals Birmingham NHS Foundation Trust, Charité, Samsung Medical Center, National Cancer Center Japan, Asan Medical Center, Mount Sinai Health System, Cedars-Sinai Medical Center, Fortis Healthcare, Stanford Health Care, AIIMS, HCA Healthcare and Institut Gustave Roussy. - The report says the market is dominated by global biopharmaceutical companies and specialized biotechnology developers focused on advanced antibody engineering platforms. - The report also cites emphasis on clinical efficacy, safety optimization, regulatory advancement and expansion into broader therapeutic applications. - The sample request and report pages are available at Request a free sample and Access the detailed report.

Between the lines: - The market structure suggests incumbents have an advantage because bispecific antibodies require costly science, long development timelines and complex manufacturing. - Acquisition activity is emerging as a key route to scale, since buying late-stage assets can accelerate pipeline growth and global rights expansion. - The report highlights BioNTech SE’s November 2024 acquisition of Biotheus for full global rights to BNT327, a bispecific antibody candidate in oncology. - The BioNTech transaction was valued at $800 million, with additional milestone payments of up to $150 million. - That deal underscores how big biotech is using M&A to deepen precision immunotherapy pipelines and strengthen commercialization prospects. - The report says companies are prioritizing dual-target engineering, T-cell engager development, clinical investment, collaborations and precision immunotherapy.

What's next: - The report expects pipeline advancement, partnership activity and technology platform expansion to reinforce the position of leading players. - Broader use of next-generation immunotherapies and multi-specific antibody technologies is likely to drive more competition for clinical and commercial share. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel forecasting dashboards, market hotspot infographics and updated trend analysis. - The company says it has published more than 30,000 reports across 27 industries and 60 geographies, supported by 1,500,000 datasets and interviews with industry leaders.

The bottom line: - Roche is still the clear leader in a market where scale, scientific depth and dealmaking matter more than broad participation.